Hubei Biocause Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Hubei Biocause Pharmaceutical has a total shareholder equity of CN¥33.7B and total debt of CN¥25.3B, which brings its debt-to-equity ratio to 75.1%. Its total assets and total liabilities are CN¥306.2B and CN¥272.5B respectively.
Key information
75.1%
Debt to equity ratio
CN¥25.30b
Debt
Interest coverage ratio | n/a |
Cash | CN¥28.29b |
Equity | CN¥33.70b |
Total liabilities | CN¥272.50b |
Total assets | CN¥306.20b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 000627's short term assets (CN¥46.4B) exceed its short term liabilities (CN¥22.7B).
Long Term Liabilities: 000627's short term assets (CN¥46.4B) do not cover its long term liabilities (CN¥249.8B).
Debt to Equity History and Analysis
Debt Level: 000627 has more cash than its total debt.
Reducing Debt: 000627's debt to equity ratio has increased from 18.1% to 75.1% over the past 5 years.
Debt Coverage: 000627's debt is well covered by operating cash flow (93.9%).
Interest Coverage: Insufficient data to determine if 000627's interest payments on its debt are well covered by EBIT.